Pirodavir (R 77975) is the prototype of a novel class of broad-spectrum antipicornavirus compounds. Although its predecessor, R 61837, a substituted phenyl-pyridazinamine, was effective in inhibiting 80% of 100 serotypes tested (EC.) at concentrations above 32 ,ug/ml, pirodavir inhibits the same percentage of viruses at 0.064 ,ug/ml. Whereas R 61837 was active almost exclusively against rhinovirus serotypes of antiviral group B, pirodavir is broad spectrum in that it is highly active against both group A and group B rhinovirus serotypes.
Pirodavir is also effective in inhibiting 16 enteroviruses, with an ECgo of 1.3 ,ug/ml. Susceptible rhinovirus serotypes were rendered noninfectious by direct contact with the antiviral compound. Their infectivity was not restored by dilution of virus-drug complexes, but was regained by organic solvent extraction of the compound for most serotypes. Neutralized viruses became stabilized to acid and heat, strongly suggesting a direct interaction of the compounds with viral capsid proteins. Mutants resistant to R 61837 (up to 85 times the MIC) were shown to bear some cross-resistance (up to 23 times the MIC) to the new compound, indicating that pirodavir also binds into the hydrophobic pocket beneath the canyon floor of rhinoviruses. Pirodavir acts at an early stage of the viral replication cycle (up to 40 min after infection) and reduces the yield of selected rhinoviruses 1,000-to 100,000-fold in a single round of replication. The mode of action appears to be serotype specific, since pirodavir was able to inhibit the adsorption of human rhinovirus 9 but not that of human rhinovirus 1A. Pirodavir is a novel capsid-binding antipicornavirus agent with potent in vitro activity against both group A and group B rhinovirus serotypes.
Rhinoviruses are a major cause of mild upper respiratory infections in humans (11) . Several synthetic antiviral agents with widely different structures have been shown to possess high in vitro activity against a selection of rhinovirus serotypes. All of them seem to bind into a specific hydrophobic pocket within the capsid protein VP1, beneath the canyon floor of rhinoviruses (24) . This binding apparently stabilizes the capsid proteins and prevents viral attachment and/or uncoating, depending on the viral serotype involved (21) .
We previously reported that rhinoviruses can be divided into two distinct groups (designated A and B) on the basis of their susceptibility profile for capsid-binding antiviral compounds (5) . Compounds such as dichloroflavan and R 61837 are active almost exclusively against serotypes from antiviral group B. Other compounds such as WIN 51711 have a complementary spectrum in that they are preferentially active against serotypes from antiviral group A only.
In a first approach to achieve broad-spectrum activity, we tried to synthesize compounds with activity against serotypes from antiviral group A. The use of such a compound with another one active against serotypes from antiviral group B (such as R 61837) would result in a mixture of compounds with broad-spectrum activity. By chemically combining substructures of R 61837 and WIN 51711, we found a lead compound with weak but specific activity against antiviral group A rhinoviruses. A rational screening program (4) involving the testing of about 600 compounds against 17 representative serotypes was used to increase its potency and eventually led to the synthesis of compounds having high activity against serotypes from both antiviral groups.
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Pirodavir (R 77975) is a substituted phenoxy-pyridazinamine, distantly related to its predecessor, R 61837, a substituted phenyl-pyridazinamine (2) (Fig. 1) . The present work compares the activity of the two compounds against rhinoviruses and enteroviruses in vitro and provides information about the mechanism of action of pirodavir.
MATERIALS AND METHODS
Viruses and cells. The origin of the rhinoviruses used in this study has been described previously (5 , were synthesized in the Janssen Laboratories by methods described elsewhere (24a, 24b). Compounds were dissolved in dimethyl sulfoxide (10 mg/ml) and diluted in growth medium to achieve the final concentration needed. Cytotoxicity assay. HeLa cells were seeded at a concentration of approximately 180,000 cells per dish in six-well plates (Falcon) containing 4 ml of growth medium. Growth medium consisted of Eagle's basal medium, supplemented with 5% fetal calf serum, 2% sodium bicarbonate, and 1% glutamine. After 24 h of incubation at 37°C in a humidified CO2 atmosphere, the growth medium was removed and replaced by the test solutions (fresh growth medium with or without various concentrations of the antiviral compounds). To assess the cytotoxicity of the antiviral compounds, we determined the number of living cells present in triplicate cultures at the time of drug addition and every 24 h for 3 days. Following trypsinization, the number of viable cells for each drug concentration was counted in triplicate with a Coulter Counter (model ELT8; Ortho). The data presented in this paper represent results obtained in two experiments that were shown to be reproducible, and each result represents the average of three replicates. Antiviral assay. An automated tetrazolium-based colorimetric assay was used for determination of MICs of test compounds. Compounds were added to a series of triplicate wells in microtiter trays. Serial fivefold dilutions were made directly in the microtiter trays with a robot system (Zymate II). Pipette tips were changed after every three dilutions. Untreated control human rhinovirus (HRV)-infected and mock-infected cell samples were included in each test. Approximately 100 50% tissue culture infective doses of virus were added to two of the three rows. After 2 h, a HeLa cell suspension (5 x 105 cells per ml) was added to all wells. The cultures were incubated at 33°C in a C02-free atmosphere. Three days after infection the viability of mock-and virus-infected cells was quantitated spectrophotometrically by a tetrazolium colorimetric method, the MTT assay (20) . The MIC was defined as the 50% inhibitory concentration for cytopathicity.
Virus yield reduction assay. HRV1A, HRV9, HRV14, HRV39, HRV89, or HRV Hank's (at a multiplicity of 1 PFU per cell) were preincubated with pirodavir at the indicated concentrations ( Fig. 2) for 30 min and then added to HeLa cells. After 1 h of adsorption at 33°C, the inoculum was removed and fresh maintenance medium containing the same concentration of pirodavir was added. The virus yield was determined by plaque assays after an additional 13 h of incubation at 33°C. The data presented represent results obtained in experiments that were shown to be reproducible in at least two occasions, and each result represents the average of three replicates.
Mechanism-of-action studies. (i) Virus neutralization. The direct virus-neutralizing effect of pirodavir was studied by using the same set of rhinovirus serotypes. Approximately 107 PFU/ml was incubated with or without different concentrations of the test compound for 60 min at 330C. After this incubation period, the reversibility of the binding between the virus and the compound was assessed by two approaches.
In the first approach, 10-fold dilutions of the virus-drug mixtures were made to obtain noninhibitory concentrations of free compound (as established in the MIC test). These dilutions were plaque titrated in HeLa cells for any remaining infectious virus. Samples treated with compound and having a lower virus titer than the untreated controls were considered to contain virus, neutralized by the compound, in a way that is irreversible by dilution.
In the second approach, we tried to restore the infectivity of neutralized viruses by extraction of the compound with organic solvents. In this case, the incubated virus-drug mixtures were mixed with an equal volume of dichloromethane. This mixture was vortexed vigorously for 1 min at room temperature and centrifuged at 1,000 x g for 5 min. The aqueous phase of the supernatant was removed, diluted 10-fold to obtain noninhibitory concentrations of free compound, and plaque titrated in HeLa cells. Virus samples treated with compound, subjected to dichloromethane extraction, and having a lower virus titer than the controls (exposed to dichloromethane extraction but not to antiviral compound) were considered to contain virus, neutralized by the compound, in a manner that was irreversible by extraction and dilution.
(ii) Stabilization against heat and acid inactivation. Approximately 107 PFU of HRV1A, HRV70, and HRV9 per ml were incubated at 330C for 60 min in minimal essential medium (MEM) of the rhinoviruses (EC50 and EC80, respectively) were 4.4 and >32 ,ug/ml for R 61837 and 0.010 and 0.064 jig/ml for pirodavir, respectively. Pirodavir is therefore about 500 times more active than R 61837. Whereas R 61837 was active almost exclusively against serotypes of antiviral group B, pirodavir was highly active against serotypes of antiviral groups A and B (Table 1 ). All enteroviruses tested were found to be susceptible to pirodavir (Table 2) , which had an EC50 and EC80 of 0.15 and 1.3 ,ug/ml, respectively. Mengovirus, foot-and-mouth disease virus types A and C, influenza A virus, and a human coronavirus were not susceptible to the compound.
Virus yield reduction assay. The effect of pirodavir on the replication of selected rhinoviruses in a single round of replication was determined (Fig. 2) . The compound reduced the viral yield by 0 (HRV Hank's) to 80% (HRV9) at concentrations equal to the MIC. Doses 10 times this concentration reduced the virus yield obtained in one replication cycle by 102-to 104-fold. On a double-logarithmic basis, it was possible to predict more than 70% of the variation in virus yield reduction from the variation in the ratio of R 77975 concentration to the MIC (r = 0.85).
Virus neutralization. Pirodavir neutralized the infectivity of the majority of serotypes studied in a manner that was irreversible by dilution. Exceptions were serotypes HRV1A, which was not neutralized irreversibly, and HRV89, which was only partially neutralized by high concentrations of pirodavir. A classical S-shaped dose-response curve between the extent of neutralization and the ratio of concentration to MIC could be observed (Fig. 3) .
Exposure of neutralized viruses to dichloromethane prior to the dilution step resulted in complete recovery of the viral infectivity for HRV Hank's. The infectivity of drug-treated HRV9 or HRV39 could be restored to 30 to 60% of the virus controls, respectively (results not shown). HRV14 and HRV89 were sensitive to the dichloromethane extraction itself, with a loss of viral infectivity of about 50%.
The effect of incubation time and drug concentration in HRV Hank's was studied (Fig. 4) . Virus neutralization was rapid at higher drug concentrations (completed within 15 min) and slower at lower drug concentrations (completed within 30 min). Low concentrations of the drug (0.1 x and 1 x the MIC) also had an effect on the infectivity of the virus, but this became clear only after very long exposure periods.
Stabilization against heat and acid inactivation. Pirodavir at the MIC was able to protect HRV9 partially against inactivation by acetate, citrate, and heat (Table 3 ). When the virus had been preincubated in lOx the MIC, the extent of protection obtained was difficult to assess because the extent of virus neutralization by pirodavir (-2.6 log10) was equal to the extent of inactivation by acid or heat.
A concentration of 1Ox the MIC was necessary to protect HRV1A and HRV70 from acetate or citrate inactivation, whereas 100X the MIC was needed to provide some protection for HRV1A against heat inactivation. The same concentration of pirodavir was insufficient to protect HRV70 from heat inactivation.
Effect of time of addition of pirodavir on virus inhibition. Maximal inhibition by pirodavir was obtained when the drug was added to the cells together with the virus (results not shown). The viral yield was also reduced when the compound was added 20 or 40 min after infection, but no more so vitro efficacy against the rhinovirus and enterovirus genera of the picornavirus family. Pirodavir is especially active against rhinoviruses, with MICs as low as 0.001 ,ug/ml (0.004 FiM) for some serotypes. Compared with its predecessor, R 61837, a substituted phenyl-pyridazinamine, a greater than 500-fold improvement in potency was obtained, as shown by the drop in EC80 from >32 ,ug/ml for R 61837 to 0.064 ,ug/ml for R 77975. The increase in potency was accompanied by a marked broadening of the spectrum. Whereas R 61837 was active almost exclusively against rhinoviruses from antiviral group B, pirodavir was highly active against rhinoviruses from both antiviral groups (Table 1) . Pirodavir, but not R 61837, was also effective in inhibiting all tested enteroviruses, although it had to be used at higher concentrations (EC80 = 1.3) than those necessary to inhibit rhinoviruses ( Table 2 ). Close chemical analogs of pirodavir are better inhibitors of enteroviruses such as poliovirus (22), but are less potent inhibitors of rhinoviruses (6) . Members of the genera cardiovirus and aphthovirus were not susceptible to pirodavir, nor were other viruses that are important in upper respiratory tract infections, such as influenza virus and human coronavirus.
The testing of a set of 17 representative serotypes (4) provided predictive information for the results subsequently obtained after testing all rhinoviruses. A pirodavir concentration of 0.143 ,ug/ml, sufficient to inhibit 14 of 17 screening serotypes (82.3%), also inhibited 84 of 101 serotypes (83.1%). Two of the 17 screening serotypes (HRV42 and HRV45) were not susceptible to pirodavir (MIC > 1 jig/ml).
Both serotypes appear at the same region (the right edge of antiviral group A) on the spectral map of serotypes and antiviral compounds (5) . Upon testing the other serotypes, it was interesting to see that most other insensitive rhinoviruses identified mapped as a cluster into the same region of antiviral group A. This finding shows that from the results obtained with the 17 serotypes, a prediction can be made about which serotypes are most likely to be resistant to a given compound.
Previously described capsid-binding molecules were shown to bind to rhinoviruses into a hydrophobic pocket beneath the canyon floor of VP1 (8, 24) . Their differential activity toward serotypes from antiviral groups A and B can be explained by their putative binding to particular amino acids lining this antiviral pocket, which are different in rhinoviruses belonging to different antiviral groups (5) . Pirodavir, on the other hand, is active against rhinoviruses from both antiviral groups. Despite having this markedly different antiviral profile, pirodavir apparently binds to the same antiviral target. Indeed, a HRV9 mutant that was resistant to R 61837 was cross-resistant to pirodavir (Table 1) . Furthermore, preliminary results of X-ray crystallographic studies indicate that pirodavir binds into the hydrophobic pocket of HRV14 (23) . The different antiviral profile, together with the sharing of the antiviral binding site, suggests that the broadspectrum activity of the compound is achieved by its binding to amino acids from the antiviral pocket that are conserved throughout rhinoviruses belonging to both antiviral groups and enteroviruses. An alignment for amino acids lining the pocket in HRV14 reveals that two tyrosines are conserved in all 11 sequenced rhinoviruses and enteroviruses (5) .
The wide range of susceptibilities of different HRV sero- (2) and slightly different from those described for chalcone, dichloroflavan, and isoflavans, which can be removed from neutralized serotypes by organic-solvent extraction (10, 17) . A classical S-shaped dose-response curve between the extent of neutralization and the ratio of pirodavir concentration to MIC could be observed (Fig. 3) .
The binding of pirodavir to viral particles results in their stabilization. Several susceptible rhinoviruses could be protected against inactivation by mild acidification or heat ( between the MICs of a given compound and the concentrations needed for stabilization of different serotypes does not exclude the possibility that such a correlation exists when several compounds of the same chemical family are being studied within one particular serotype (12) .
A time-of-addition study indicated that pirodavir had an effect on an early event in the replication of both HRV1A and HRV9. In HRV9, the adsorption step was inhibited by pirodavir concentrations closely related to the MIC (Fig.  SA) . On the other hand, the adsorption of HRV1A was not inhibited at concentrations greatly exceeding the MIC, indicating that the mode of action is serotype specific. A similar differential effect on rhinovirus serotypes has also been described for WIN 54954, another potent capsid-binding compound (21) . The extent of conformational changes induced in the putative receptor-binding region for these viruses, the canyon structure (9), may be responsible for the observed differences in the mode of action.
During the past decade, several compounds from different chemical classes with potent in vitro activity against several members of the picornavirus family have been described. They include flavans (7), isoflavans (10), chalcone (14) , chalcone amides (18), pyrano-pyridines (15) , and isoxazoles (19, 25) . All of them are supposed to exert their antiviral activity by binding to virions, inducing conformational and flexibility changes in the capsid proteins and thus inhibiting the adsorption and/or uncoating event of the replication cycle (21) . Drug-resistant mutants raised against some of these compounds usually exhibit cross-resistance to others, strongly suggesting a similar mode of action and a sharing of binding sites (3, 17, 18) . Few of the compounds mentioned have been advanced to in vivo studies. Several compounds of the WIN series have proved to be efficacious in various animal models of enteroviral disease (16, 25) . R 61837, the prototype compound of the pyridazinamine series, has shown clinical efficacy in humans (1) . A pilot clinical trial of pirodavir under double-blind, placebo-controlled conditions indicated that the compound has a clinical effect in humans (13) . Although pirodavir is inactive against common cold viruses other than rhinoviruses, it can be considered a (22) .
